Eye Hospital, China Academy of Chinese Medical Sciences, 33 Lugu Road, Shijingshan District, Beijing, 100040, China.
Hamilton Glaucoma Center, The Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California, San Diego, CA, USA.
Sci Rep. 2023 Jul 27;13(1):12179. doi: 10.1038/s41598-023-38550-7.
This prospective, observer-masked, randomized clinical trial was conducted between December 2018 and June 2021 at Eye Hospital, China Academy of Chinese Medical Sciences. A total of 45 glaucoma patients from Beijing, China, were enrolled in this clinical trial to compare the short-term efficacy of primary single-selective laser trabeculoplasty (SLT) to 0.005% latanoprost eye drops for the treatment of 24-h intraocular pressure (IOP) in patients with newly diagnosed primary open angle glaucoma (POAG) and ocular hypertension (OHT). Both SLT and latanoprost significantly decreased mean 24-h IOP and peak IOP, although the latanoprost group effect was more potent when compared to the SLT group (both Ps < 0.05). Compared with the SLT group, the latanoprost group had a significant and stable decrease in IOP after treatment. The latanoprost group had a more pronounced reduction in IOP at weeks 4 and 12 (P < 0.05) but had no difference at week 1 (P = 0.097). As a first-line treatment, both SLT and latanoprost eye drops are effective in newly diagnosed POAG and OHT patients. However, the latanoprost eye drops may be better in decreasing mean and peak 24-h IOP and thus controlling 24-h IOP fluctuation compared to SLT.
这项前瞻性、观察者设盲、随机临床试验于 2018 年 12 月至 2021 年 6 月在中国中医科学院眼科医院进行。共有来自中国北京的 45 名青光眼患者入组本临床试验，以比较原发性单选择性激光小梁成形术（SLT）与 0.005%拉坦前列素滴眼液治疗新发原发性开角型青光眼（POAG）和高眼压症（OHT）患者 24 小时眼压（IOP）的短期疗效。虽然与 SLT 组相比，拉坦前列素组的效果更显著（均 P<0.05），但 SLT 和拉坦前列素均显著降低了平均 24 小时 IOP 和峰 IOP。与 SLT 组相比，拉坦前列素组在治疗后眼压下降更明显且稳定。拉坦前列素组在治疗后第 4 周和第 12 周的 IOP 下降更为明显（P<0.05），但在第 1 周没有差异（P=0.097）。作为一线治疗，SLT 和拉坦前列素滴眼液对新发 POAG 和 OHT 患者均有效。然而，与 SLT 相比，拉坦前列素滴眼液可能在降低平均和峰值 24 小时 IOP 以及控制 24 小时 IOP 波动方面效果更好。
